Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37700   clinical trials with a EudraCT protocol, of which   6177   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11 months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV/Hib vaccine, in study 105539 (10PN-PD-DIT-002).

    Due to a system error, the data reported in v1 is not correct and has been removed from public view.
    Summary
    EudraCT number
    2011-000943-26
    Trial protocol
    SE   NO  
    Global end of trial date
    15 Jul 2011

    Results information
    Results version number
    v2(current)
    This version publication date
    08 Jul 2016
    First version publication date
    13 Feb 2015
    Other versions
    v1 (removed from public view)
    Version creation reason
    • New data added to full data set
    • Correction of full data set
    - Data correction due to a system error in EudraCT – Results - Data for primary endpoints have been added: Number of subjects with anti-HBs antibody concentrations ≥ 6.2 mIU/mL

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    115375
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01358825
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    GlaxoSmithKline Biologicals
    Sponsor organisation address
    Rue de l'institut 89, Rixensart, Belgium, 1330
    Public contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 004 8773793718, GSKClinicalSupportHD@gsk.com
    Scientific contact
    Clinical Trials Call Center, GlaxoSmithKline Biologicals, 004 8773793718, GSKClinicalSupportHD@gsk.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    09 Aug 2012
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    15 Jul 2011
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Jul 2011
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the immunogenicity of the DTPa-HBV-IPV/Hib and DTPa-IPV/Hib vaccines in terms of persistence of antibodies to all vaccine antigens in 5-year-old children.
    Protection of trial subjects
    Since the study does not involve active vaccination, serious adverse events (SAEs) related to study procedures and/or concomitant GSK medication were documented and described in detail.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    30 May 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Norway: 46
    Country: Number of subjects enrolled
    Sweden: 12
    Worldwide total number of subjects
    58
    EEA total number of subjects
    58
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    58
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Infanrix hexa Group
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Infanrix™ Hexa
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Subjects from Sweden previously vaccinated with 3 doses of Infanrix™ hexa vaccine in the primary study (NCT00307034).

    Arm title
    Infanrix-IPV/Hib Group
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Infanrix™ IPV/Hib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    Subjects from Norway previously vaccinated with 3 doses of Infanrix™-IPV/Hib vaccine in the primary study (NCT00307034).

    Number of subjects in period 1
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Started
    12
    46
    Completed
    12
    45
    Not completed
    0
    1
         Blood sample not drawn
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Infanrix hexa Group
    Reporting group description
    -

    Reporting group title
    Infanrix-IPV/Hib Group
    Reporting group description
    -

    Reporting group values
    Infanrix hexa Group Infanrix-IPV/Hib Group Total
    Number of subjects
    12 46 58
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    5 ± 0 5 ± 0 -
    Gender categorical
    Units: Subjects
        Female
    9 14 23
        Male
    3 32 35

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Infanrix hexa Group
    Reporting group description
    -

    Reporting group title
    Infanrix-IPV/Hib Group
    Reporting group description
    -

    Primary: Number of seroprotected subjects against anti-diphtheria (anti-D) and anti-tetanus (anti-T).

    Close Top of page
    End point title
    Number of seroprotected subjects against anti-diphtheria (anti-D) and anti-tetanus (anti-T). [1]
    End point description
    A seroprotected subject is a subject with anti-D/anti-T antibody concentrations greater than (≥) or equal to 0.1 international units per milliliter (IU/mL)
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: subjects
        Anti-D [N=12;45]
    7
    28
        Anti-T [N=12;44]
    10
    34
    No statistical analyses for this end point

    Primary: Concentrations of antibodies against anti-D and anti-T

    Close Top of page
    End point title
    Concentrations of antibodies against anti-D and anti-T [2]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: IU/mL
    geometric mean (confidence interval 95%)
        Anti-D [N=12;45]
    0.13 (0.072 to 0.235)
    0.196 (0.114 to 0.338)
        Anti-T [N=12;44]
    0.29 (0.135 to 0.624)
    0.352 (0.207 to 0.599)
    No statistical analyses for this end point

    Primary: Number of subjects with anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations ≥5 ELISA units per milliliter (EL.U/mL).

    Close Top of page
    End point title
    Number of subjects with anti-pertussis toxoid (anti-PT), anti-filamentous haemagglutinin (anti-FHA) and anti-pertactin (anti-PRN) antibody concentrations ≥5 ELISA units per milliliter (EL.U/mL). [3]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: subjects
        Anti-PT
    0
    9
        Anti-FHA
    12
    41
        Anti-PRN
    8
    34
    No statistical analyses for this end point

    Primary: Concentrations of antibodies against anti-PT, anti-FHA and anti-PRN.

    Close Top of page
    End point title
    Concentrations of antibodies against anti-PT, anti-FHA and anti-PRN. [4]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: EL.U/mL
    geometric mean (confidence interval 95%)
        Anti-PT
    2.5 (2.5 to 2.5)
    4.2 (2.9 to 6)
        Anti-FHA
    32.6 (11.5 to 92.5)
    50.7 (30.6 to 84.1)
        Anti-PRN
    6.2 (3.9 to 9.9)
    11.9 (8.4 to 16.8)
    No statistical analyses for this end point

    Primary: Number of seroprotected subjects against anti-hepatitis B surface antigen (anti-HBs).

    Close Top of page
    End point title
    Number of seroprotected subjects against anti-hepatitis B surface antigen (anti-HBs). [5] [6]
    End point description
    Seroprotection = anti-HBs antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Anti-HBs concentrations assessed only in subjects who previously received a HBs-containing vaccine
    End point values
    Infanrix hexa Group
    Number of subjects analysed
    12
    Units: subjects
        Anti-HBs
    5
    No statistical analyses for this end point

    Primary: Concentrations of antibodies against anti-HBs.

    Close Top of page
    End point title
    Concentrations of antibodies against anti-HBs. [7] [8]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Anti-HBs concentrations assessed only in subjects primed with a HBs-containing vaccine
    End point values
    Infanrix hexa Group
    Number of subjects analysed
    12
    Units: mIU/mL
    geometric mean (confidence interval 95%)
        Anti-HBs
    9 (3.9 to 20.9)
    No statistical analyses for this end point

    Primary: Number of seroprotected subjects against anti-polyribosyl ribitol phosphate (anti-PRP).

    Close Top of page
    End point title
    Number of seroprotected subjects against anti-polyribosyl ribitol phosphate (anti-PRP). [9]
    End point description
    A seroprotected subject is a subject with anti-PRP antibody concentrations ≥ 0.15 micrograms per milliliter (µg/mL)
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: subjects
        Anti-PRP
    10
    40
    No statistical analyses for this end point

    Primary: Concentrations of antibodies against anti-PRP.

    Close Top of page
    End point title
    Concentrations of antibodies against anti-PRP. [10]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    45
    Units: µg/mL
    geometric mean (confidence interval 95%)
        Anti-PRP
    0.404 (0.22 to 0.743)
    0.886 (0.558 to 1.407)
    No statistical analyses for this end point

    Primary: Number of subjects with serious adverse events (SAEs).

    Close Top of page
    End point title
    Number of subjects with serious adverse events (SAEs). [11]
    End point description
    Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
    End point type
    Primary
    End point timeframe
    During the entire study period
    Notes
    [11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    End point values
    Infanrix hexa Group Infanrix-IPV/Hib Group
    Number of subjects analysed
    12
    46
    Units: subjects
        SAEs
    0
    0
    No statistical analyses for this end point

    Primary: Number of subjects with anti-HBs antibody concentrations ≥ 6.2 mIU/mL

    Close Top of page
    End point title
    Number of subjects with anti-HBs antibody concentrations ≥ 6.2 mIU/mL [12] [13]
    End point description
    End point type
    Primary
    End point timeframe
    At Day 0
    Notes
    [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The analysis of the primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Anti-HBs concentrations assessed only in subjects primed with a HBs-containing vaccine
    End point values
    Infanrix hexa Group
    Number of subjects analysed
    12
    Units: Subjects
        Anti-HBs
    6
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    SAEs: during the entire study period
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    14
    Reporting groups
    Reporting group title
    Infanrix-IPV/Hib Group
    Reporting group description
    -

    Reporting group title
    Infanrix hexa Group
    Reporting group description
    -

    Serious adverse events
    Infanrix-IPV/Hib Group Infanrix hexa Group
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 12 (0.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Infanrix-IPV/Hib Group Infanrix hexa Group
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    0 / 46 (0.00%)
    0 / 12 (0.00%)
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: Adverse events were not collected as the study did not involve any vaccination.

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA